<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">OXYMETHOLONE</span><br/>(ox-i-meth'oh-lone)<br/><span class="topboxtradename">Anadrol, </span><span class="topboxtradename">Anadrol-50, </span><span class="topboxtradename">Anapolon <img border="0" src="../images/maple.gif"/><br/></span><b>Classifications:</b> <span class="classification">hormones and synthetic substitutes</span>; <span class="classification">androgen/anabolic steroid</span><br/><b>Prototype: </b>Testosterone<br/><b>Pregnancy Category: </b>X<br/><b>Controlled Substance: </b>Schedule III<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>50 mg tablets</p>
<h1><a name="action">Actions</a></h1>
<p>Potent steroid with anabolic activity. Mechanism of action in refractory anemias is unclear but may be due to direct stimulation
         of bone marrow, protein anabolic activity, or to androgenic stimulation of erythropoiesis.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Promotes body tissue building and inhibits tissue-depleting processes; supports nitrogen, potassium, chloride, and phosphorus
         conservation. Enhances weight gain and combats depression and weakness in debilitating conditions. Stimulates bone growth,
         aids in bone matrix reconstitution, and may support calcification of metastatic lesions of breast cancer.
      </p>
<h1><a name="uses">Uses</a></h1>
<p>Aplastic anemia.</p>
<h1><a name="unlabeleduses">Unlabeled Uses</a></h1>
<p>Osteoporosis, catabolic conditions.</p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Prostatic hypertrophy with obstruction; pregnancy (category X); prostatic or male breast cancer; cardiac, renal, hepatic decompensation;
         nephrosis; premature infant; use during lactation is not established.
      </p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>Prepubertal males; geriatric male patients; diabetes mellitus; coronary disease; patient taking ACTH, corticosteroids, anticoagulants.</p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Aplastic Anemia</span><br/><span class="rdage">Adult/</span><span class="rdage">Child:</span> <span class="rdroute">PO</span> 15 mg/kg/d<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Oral</span><br/><ul>
<li>A course of therapy for treatment of osteoporosis is 721 d.</li>
<li>For treatment of anemias, a minimum trial period of 36 mo is recommended, since response tends to be slow.</li>
<li>Store at 15°30° C (59°86° F). Protect from heat and light.</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">Endocrine:</span> Androgenic in women: Suppression of ovulation, lactation, or menstruation; <span class="speceff-common">hoarseness or deepening of voice</span> (often irreversible); <span class="speceff-common">hirsutism; oily skin; acne;</span> clitoral enlargement; regression of breasts; male-pattern baldness (in disseminated breast cancer). Hypoestrogenic effects
      in women: Flushing, sweating; vaginitis with pruritus, drying, bleeding; menstrual irregularities. Men: prepubertal: premature
      epiphyseal closure, phallic enlargement, priapism. Postpubertal: testicular atrophy, decreased ejaculatory volume, azoospermia,
      oligospermia (after prolonged administration or excessive dosage), impotence, epididymitis, gynecomastia. <span class="typehead">CV:</span> <span class="speceff-common">Edema,</span> skin flush. <span class="typehead">GI:</span> <span class="speceff-common">Nausea, vomiting, anorexia,</span> diarrhea, jaundice, <span class="speceff-life">hepatotoxicity</span>. <span class="typehead">Urogenital:</span> Bladder irritability. <span class="typehead">Metabolic:</span> Hypercalcemia. 
      <h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span> May enhance hypoprothrombinemic effects of <b>warfarin.</b> <span class="typehead">Herbal:</span> <b>Echinacea</b> may increase risk of hepatotoxicity. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption:</span> Readily absorbed from GI tract. <span class="typehead">Metabolism:</span> Metabolized in liver. <span class="typehead">Elimination:</span> Excreted in urine. <span class="typehead">Half-Life:</span> 9 h. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Monitor patient with a history of seizures closely because an increase in their frequency may be noted.</li>
<li>Monitor periodically for edema that may develop with or without CHF.</li>
<li>Monitor for hypercalcemia (see Appendix F), especially in women with breast cancer.</li>
<li>Lab tests: Periodic serum calcium; periodic liver function tests are especially important for the older adult patient. Drug
            should be stopped with first sign of liver toxicity (jaundice).
         </li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Monitor blood glucose for loss of glycemic control if diabetic.</li>
<li>Women: Notify physician of signs of virilization.</li>
<li>Do not breast feed while taking this drug without consulting physician.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>